Corey S. Cutler, MD, MPH, FRCPC

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.

Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.

Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.

A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the results of the ROCKstar study in chronic graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.